News

The neurologist from Banner Health and chief medical officer of the MS Association of America provided perspective on the global impact World MS Day can have on the patient and clinician community.

After propensity adjustment, there was no difference in the risk of epilepsy or age at epilepsy onset for infants whose ASM was discontinued vs maintained at hospital discharge.

Richard Gershon, PhD, vice chair for research at the Northwestern University Feinberg School of Medicine, discussed the development of the mobile toolbox battery to track cognitive decline.

Neurology News Network for the week ending May 29, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 28, 2021.

The professor of neurology at Mayo Clinic detailed the next steps in understanding more about the impact social determinants of health have on epilepsy care.

Biohaven’s agent is now the first oral CGRP antagonist to be approved for prevention, and the first to be approved for both acute and preventive therapy. It is marketed as Nurtec ODT and is administered in a 75-mg dose.

Mary Meskis, executive director of the Dravet Syndrome Foundation, provided a opportunities the organization is offering in honor of Dravet Syndrome Awareness Month.

The head of global research and executive vice president of Atara Biotherapeutics discussed the trial design of part 2 of the study of ATA188.

Six months after being discharged from the hospital for COVID-19, patients scored worse than average on 1 or more NeuroQoL scale components, which measured anxiety, sleep, fatigue, and depression.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed the role of clinicians in determining migraine treatment eligibility.

Alterations in MDS-UPDRS part III scores were associated with increased expression of Treg phenotypes and immunosuppressive function, suggesting a potential role of Treg function in diminution of disease progression.

The American Heart Association/American Stroke Association has published updated guidelines for the prevention of secondary stroke.

The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed the findings of the post-hoc analysis of the ORATORIO study.

The long-term follow up of the phase 1 START trial found that previously achieved motor milestones were preserved over a 5-year period.

The senior director of patient management, care, and rehabilitation research at the National Multiple Sclerosis Society encouraged clinicians to spread word of the need for research.

In addition to focusing on healthy sleep habits, researchers reinforce empowering children and adolescents to navigate the “brave new world” of online and hybrid schooling influenced by the pandemic.

Matthew B. Harms, MD, associate professor of neurology at Columbia and medical consultant for the Muscular Dystrophy Association, shares his thoughts on the current state of ALS care.

The founder and chief scientific officer of Neurolutions discussed the mechanisms by which the IpsiHand System effectively assists patients with chronic stroke.

The neurologist from Banner Health and chief medical officer of the MS Association of America discussed the significance of World MS Day and how clinical care of MS has evolved.

Stephen Rao, PhD, ABPP-Cn, the Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic, discussed the development of the MSPT.

A 5-year, post-approval study of the remedē System confirmed results of the pivotal trial.

The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed the background of the ORATORIO study and the aT2-LV biomarker.

With successful completion of the phase 2a study, Annovis plans on evaluating ANVS401 in late-stage studies starting in late 2021.

The neurologist at Cleveland Clinic discussed how his data may change clinicians’ perception on the management and prevalence of generalized epilepsy in elders.

Lawrence Severt, MD, PhD, discussed the history of CGRP antagonists and what atogepant can potentially bring to the market pending approval.

Researchers could not identify any risk factors for contracting COVID-19 in the population with epilepsy.

The senior director of patient management, care, and rehabilitation research at the National Multiple Sclerosis Society discussed the importance of fundraising events to further MS research.

An upcoming phase 2 trial will assess ketamine in up to 36 patients, using change in the Unified Dyskinesia Rating Scale as the primary end point of the study.

Sana Somani, MD, MBBS, vascular neurology fellow at the University of Maryland Medical Center, discussed her research into disparities in post-stroke care.